Thus, CD4+ OX40 and sOX40L may be expected to be biomarkers for monitoring relapse in MG patients after immunosuppressive therapy, and further studies in large cohorts are required in the future. The gene discussed is TNFRSF4; the disease is myasthenia gravis.